Lotus Yung

Lotus Yung is an experienced professional in the field of clinical research and development, currently serving as Vice President and Cell Therapy Development Team Leader at Galapagos since April 2025. Previously, Lotus held positions as Program Lead for Early Oncology Development at Daiichi Sankyo, and Senior Director for ENHERTU Asset Lead in Women's Health at Daiichi Sankyo, Inc., leading clinical trials and managing clinical scientists. Earlier roles include Senior Director at Rocket Pharmaceuticals, Executive Director at Iovance Biotherapeutics, and Director/Principal Clinical Research Scientist at Celgene, where Lotus contributed to significant clinical trials including the bb2121 Phase 2 registration trial in immuno-oncology. Other notable experience includes leadership positions at Bristol-Myers Squibb and Novartis, with a strong focus on protocol development, clinical operations, and stakeholder engagement. Lotus Yung holds a Doctor of Pharmacy (Pharm.D.) from the University of California, San Francisco, and a Master of Science (M.S.) in Nutrition Sciences from Columbia University.